Page last updated: 2024-12-05

dextropropoxyphene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10100
CHEMBL ID1213351
CHEBI ID51173
CHEBI ID8497
SCHEMBL ID25405
MeSH IDM0017770

Synonyms (106)

Synonym
dextropropoxifeno
dextroproxifeno
CHEBI:51173 ,
dextropropoxyphenum
alpha-d-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat
sk-65
CHEMBL1213351
depromic
propoxyphene, d-
j5.928e ,
2-butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2s,3r)-
(1s,2r)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate
(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane
dextropropoxifeno [inn-spanish]
einecs 207-420-5
benzeneethanol, alpha-((1r)-2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (alphas)-
2-butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate, (+)-
(d)-propoxyphene
darvon
propoxyphene, (+)-
femadol
sk 65
proxagesic
alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester
alpha-d-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate
(+)-1,2-diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane
dextropropoxyphene [inn:ban]
benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (s-(r*,s*))-
alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane
hsdb 3175
destropropossifene [dcit]
algafan
alpha-4-dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate
dextropropoxyphenum [inn-latin]
dea no. 9273
antalvic
dextropropoxyphen
4-dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
alpha-d-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [german]
bulk dextropropoxyphene (non-dosage forms)
(s)-alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate
dextroproxifeno [spanish]
usaf el-84
469-62-5
propoxyphene
dextropropoxyphene
destropropossifene
d-propoxyphene
DB00647
d propoxyphene
dextropropoxyphene (inn)
propoxypene
propoxyphene-d
bdbm82269
cas_469-62-5
ii2g62ov6f ,
unii-ii2g62ov6f
2621-61-6
unii-s2f83w92tk
proxyvon
s2f83w92tk ,
dextropropoxyphene [who-dd]
propoxyphene [hsdb]
dextropropoxyphene [mart.]
(+)-propoxyphene
dextropropoxyphene [inn]
benzeneethanol, .alpha.-((1r)-2-(dimethylamino)-1-methylethyl)-.alpha.-phenyl-, 1-propanoate, (.alpha.s)-
propoxyphene [mi]
propoxyphene [vandf]
(2s,3r)-(+)-4-(dimethylamino)-3-methyl-1,2-diphenyl-2-butanol propionate (ester)
ids-nd-004(sect.2)
(+/-)-propoxyphene
propoxyphene, (+/-)-
benzeneethanol, .alpha.-((1r)-2-(dimethylamino)-1-methylethyl)-.alpha.-phenyl-, 1-propanoate, (.alpha.s)-rel-
[(2s,3r)-4-dimethylamino-3-methyl-1,2-di(phenyl)butan-2-yl] propanoate
(+)-alpha-propoxyphene
gtpl7593
SCHEMBL25405
abalgin (salt/mix)
erantin (salt/mix)
darvon (salt/mix)
(+)-4-(dimethylamino)-3-methyl-1,2-diphenyl-2-butanol propionate
.alpha.-d-propoxyphene
(2s,3r)-(+)-4-(dimethylamino)-3-methyl-1,2-diphenyl-2-butanol propionate(ester)
doloxen (salt/mix)
romidon (salt/mix)
doloxene (salt/mix)
1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propionate, [s-(r*,s*)]- #
dolene (salt/mix)
.alpha.-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester
benzeneethanol, .alpha.-[2-(dimethylamino)-1-methylethyl]-.alpha.-phenyl-, propanoate, [s-(r*,s*)]-
DTXSID1023524 ,
dextropropoxyphene 0.1 mg/ml in acetonitrile
dextropropoxyphene 1.0 mg/ml in acetonitrile
Q2268608
dextropropoxyphene (mart.)
dextropropoxyphenum (inn-latin)
dtxcid503524
dextropropoxifeno (inn-spanish)
(s)-alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate (ester)
(alpha-s) alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate (ester)
chebi:8497
benzeneethanol, alpha-((1r)-2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, 1-propanoate, (alphas)-
rac-(1r,2r)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate
d-propoxy phene
alpha-d-propoxphene

Research Excerpts

Overview

Dextropropoxyphene (DP) is a commonly used medicament for suicide attempts in Denmark. It is a widely prescribed synthetic opiate-like drug of uncertain analgesic efficacy which, in acute overdosage, manifests all the features of opiate toxicity.

ExcerptReferenceRelevance
"Dextropropoxyphene is a weak opioid analgesic, widely used as a step 2 analgesic (according to WHO classification) in combination with peripheral analgesics, mainly paracetamol. "( Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption.
Damase-Michel, C; Gaubert, S; Montastruc, JL; Pathak, A; Vié, M, 2009
)
3.24
"Dextropropoxyphene poisoning is an uncommon accidental poisoning in children. "( Accidental dextropropoxyphene poisoning.
Hegde, SR; Karunakara, BP; Maiya, PP; Pradeep, GC, 2003
)
2.15
"Dextropropoxyphene is a widely prescribed synthetic opiate-like drug of uncertain analgesic efficacy which, in acute overdosage, manifests all the features of opiate toxicity. "( Dextropropoxyphene overdosage. Pharmacological considerations and clinical management.
Young, RJ, 1983
)
3.15
"Dextropropoxyphene is a commonly used analgesic despite its high toxicity in overdose and potential for abuse and dependence. "( The dangers of dextropropoxyphene.
Dore, GM, 1996
)
2.09
"Dextropropoxyphene (DP) is a commonly used medicament for suicide attempts in Denmark. "( Pharmacokinetics of dextropropoxyphene in acute poisoning.
Angelo, H; Christensen, JM; Dam, W; Jensen, K; Schou, J, 1978
)
2.02

Effects

Dextropropoxyphene has not been reported previously as a cause of hypersensitivity pneumonitis. It is increasingly prescribed as an analgesic in the UK, chiefly in the form of Distalgesic.

ExcerptReferenceRelevance
"Dextropropoxyphene has been increasingly prescribed as an analgesic in the UK, chiefly in the form of Distalgesic (dextropropoxyphene hydrochloride 32.5 mg and paracetamol 325 mg per tablet). "( Dextropropoxyphene deaths: coroner's report.
Whittington, RM, 1984
)
3.15
"Dextropropoxyphene has not been reported previously as a cause of hypersensitivity pneumonitis."( Hypersensitivity pneumonitis associated with co-proxamol (paracetamol + dextropropoxyphene) therapy.
Crompton, GK; Matusiewicz, SP; Wallace, WA, 1999
)
1.26

Toxicity

The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines from the market for safety reasons. The frequency of reports appears similar to that of other opioids.

ExcerptReferenceRelevance
"The toxic effects of alpha-d-propoxyphene (P) and its primary metabolite alpha-d-norpropoxyphene (NP) were compared to intravenous infusions (100 min."( Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits.
Lund-Jacobsen, H, 1978
)
0.26
" Three patients (one on ketorolac, two on Doleron) withdrew because of adverse events (vomiting)."( Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain.
Johansson, S; Josefsson, G; Lindstrand, A; Malstam, J; Stenstroem, A,
)
0.13
" Intracerebrally and suboccipitally injected variamycin and mitramycin induced marked toxic reactions, even the death of animals, and cannot be recommended for the neurooncological clinic."( [Toxicity of anti-tumor preparations after intracranial, subarachnoid and suboccipital administration (experimental study)].
Annin, EA; Egorenko, GG; Romodanov, SA; Semenova, VM; Verkhogliadova, TP,
)
0.13
" Suprofen was generally found to be at least as safe and as well tolerated as reference drugs of aspirin, propoxyphene and propoxyphene combination."( Suprofen. An overview of long-term safety.
Gardner, MC; Milak, DM; Raina, M; Smith, KE; Yeadon, A, 1983
)
0.27
" Furthermore, a lack of central nervous system cellular tolerance was demonstrated by the finding that intracerebroventricular LD50 values for propoxyphene in propoxyphene- and water-treated mice were identical to the value derived from naive mice."( Effect of repeated oral propoxyphene administration on analgesia, toxicity and microsomal metabolism in the mouse.
Masten, LW, 1980
)
0.26
" Toxic blood concentrations ranging from 3 to 180 mumol/l have been reported and the accumulation of NP in cardiac tissue leads to naloxone-insensitive cardiotoxicity."( Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents.
Daenens, P; Tytgat, J; Ulens, C, 1999
)
0.3
" Although the adverse event profile suggests that elderly patients might have more frequent gastrointestinal and CNS complaints than younger patients treated with dextropropoxyphene, the frequency of reports appears similar to that of other opioids."( Dextropropoxyphene: safety and efficacy in older patients.
Goldstein, DJ; Turk, DC, 2005
)
1.97
" The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often."( Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Arnaud, M; Bégaud, B; Bezin, J; Haramburu, F; Pageot, C; Pariente, A; Salvo, F; Smith, A, 2017
)
0.46
"The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons."( Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Arnaud, M; Bégaud, B; Bezin, J; Haramburu, F; Pageot, C; Pariente, A; Salvo, F; Smith, A, 2017
)
0.65
"Dihydrocodeine and tramadol are particularly toxic in overdose and codeine is also relatively toxic."( Relative toxicity of analgesics commonly used for intentional self-poisoning: A study of case fatality based on fatal and non-fatal overdoses.
Bankhead, C; Casey, D; Clements, C; Ferrey, A; Fuller, A; Geulayov, G; Gunnell, D; Hawton, K; Kapur, N; Ness, J; Wells, C, 2019
)
0.51
" Regression models estimated daily milligrams morphine equivalent (MME), daily prescription acetaminophen dose, potentially toxic acetaminophen doses, nonopioid prescription analgesics receipt, emergency room visits, and diagnosed falls, motor vehicle accidents, and hip fractures."( Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events.
Hooten, WM; Jeffery, MM; Larochelle, M; Meara, E; Morden, NE; Shah, ND, 2020
)
0.56
" Adverse events were rare and not significantly different in exposed versus unexposed groups."( Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events.
Hooten, WM; Jeffery, MM; Larochelle, M; Meara, E; Morden, NE; Shah, ND, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Hypocapnia was found to lead to a significant increase in the plasma half-life of DP."( Pharmacokinetics of dextropropoxyphene in acute poisoning.
Angelo, H; Christensen, JM; Dam, W; Jensen, K; Schou, J, 1978
)
0.58
" There were no significant differences in median D and ND half-life, AUC, Cmax and tmax between the male and female subjects in either group."( Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.
Crome, P; Flanagan, RJ; Johnston, A; White, AS, 1989
)
0.6
"5 g at 6 h intervals, charcoal significantly shortened the terminal serum half-life of dextropropoxyphene from 31."( Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.
Kärkkäinen, S; Neuvonen, PJ, 1985
)
0.76
" Ethanol did not induce any significant changes in apparent t 1/2 or Cmax of propoxyphene or norpropoxyphene."( Pharmacokinetic interaction of propoxyphene with ethanol.
Degani, NC; Foltz, RL; Hamilton, CA; Kaplan, HL; Sellers, EM, 1985
)
0.27
"The acute behavioral cardiopulmonary and pharmacokinetic effects of propoxyphene hydrochloride were studied in seven adult horses."( Cardiopulmonary, behavioral, and pharmacokinetic effects of propoxyphene in horses.
Huffman, R; Muir, WW; Sams, RA, 1980
)
0.26
" Failure to specify the lag time can lead to inappropriate or erroneous estimates of pharmacokinetic parameters."( The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model.
Block, LH; Nerella, NG; Noonan, PK, 1993
)
0.29
"To evaluate intrapleural analgesia with bupivacaine following partial pulmonary resection and to determine pharmacokinetic parameters of bupivacaine with epinephrine."( Interpleural analgesia with bupivacaine following thoracotomy: ineffective results of a controlled study and pharmacokinetics.
Debaene, B; Elman, A; Magny-Metrot, C; Murciano, G,
)
0.13
" Maximum peak concentration (C Max) and maximum time to reach the peak concentration (T Max) were assessed after the first and last injections."( Interpleural analgesia with bupivacaine following thoracotomy: ineffective results of a controlled study and pharmacokinetics.
Debaene, B; Elman, A; Magny-Metrot, C; Murciano, G,
)
0.13
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The respiratory and psychomotor effects of a single oral dose of meptazinol (200 mg) and dextropropoxyphene (65 mg)/paracetamol (650 mg) mixture, was compared alone and in combination with ethanol (0."( Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements.
Ali, NA; Allen, EM; Graham, DF; Marshall, RW; Richens, A, 1985
)
0.73
" Thus, in vitro-in vivo extrapolation approaches were used to identify potential drug-drug interactions arising from inhibition of COD glucuronidation in humans."( In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.
Elliot, DJ; Janchawee, B; Miners, JO; Raungrut, P; Somogyi, AA; Uchaipichat, V, 2010
)
0.57

Bioavailability

ExcerptReferenceRelevance
" The potential bioavailability problems with water-soluble drugs and the lack of correlation of in vitro and in vivo parameters for equivalent drug formulations are discussed."( Generic propoxyphene: need for clinical bioavailability evaluation.
DeSante, KA; DiSanto, AR; Kaiser, DG; Stoll, RG, 1977
)
0.26
"The influence of food intake on the bioavailability of three analgesic compounds--propoxyphene chloride, acetyl salicylic acid and phenazone--in a combination tablet, Doleron, has been examined in eight healthy volunteers."( Bioavailability of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): interindividual variation and influence of food intake.
Berlin-Wahlén, A; Bodin, NO; Danielson, K; Gustafsson, B; Lindgren, S; Melander, A; Westerlund, D, 1977
)
0.26
"Ten commercial products containing 65 mg propoxyphene hydrochloride have been evaluated for their relative bioavailability in human subjects in a complete crossover study."( Propoxyphene bioavailability: an evaluation of ten products.
Melikian, AP; Meyer, MC; Slywka, GW; Whyatt, PL,
)
0.13
" The bioavailability of tablets and a solution of propranolol was compared with a crossover design by obtaining plasma samples at the end of the dosage interval during chronic oral administration of various doses."( Disposition of propoxyphene and propranolol in children.
Atwood, GF; Shand, DG; Wilson, JT, 1976
)
0.26
"The influence of various test meals and ingested fluid volumes on the bioavailability and pharmacokinetics of propoxyphene and its major metabolite norporpoxyphene has been studied in healthy human subjects."( Propoxyphene and norpropoxyphene: influence of diet and fluid on plasma levels.
Craig, WA; Lyons, LL; Tse, FL; Welling, PG, 1976
)
0.26
" Ethanol was shown to enhance the bioavailability of propoxyphene by 25% probably by reducing its first-pass metabolism."( Enhancement of propoxyphene bioavailability by ethanol. Relation to psychomotor and cognitive function in healthy volunteers.
Bertaux, L; Dellatolas, F; Fournier, PE; Girre, C; Hirschhorn, M; Moreno, M; Ngo, R; Palombo, S, 1991
)
0.28
"5 g/kg) had no effect on the bioavailability of propoxyphene."( The effect of ethanol intake on propoxyphene absorption and biotransformation in dogs.
Aune, H; Bodd, E; Gulliksen, M; Lilleaasen, P; Mørland, J; Olsen, H, 1986
)
0.27
" Absolute DP bioavailability obtained after oral administration was two times higher than that observed after portal administration (48."( 14C-Propoxyphene demethylation in the rat. An example of differences between liver and intestinal drug-presystemic metabolism.
Desager, JP; Geubel, AP; Horsmans, Y; Lambotte, L; Pauwels, S; Saliez, A; van den Berge, V, 1997
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31

Dosage Studied

Serious side effects may result from the concurrent administration of the usual dosage of carbamazepine and dextropropoxyphene. The mean elimination half-life of Dextro Propoxyphen (DPP) after multiple dosing was 35.

ExcerptRelevanceReference
" These data do not provide pharmacokinetic support for a general reduction of the Doleron dosage in elderly subjects."( Absorption and elimination of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): comparison between young and elderly subjects.
Bodin, NO; Danielson, K; Gustafsson, B; Haglund, G; Melander, A; Westerlund, D, 1978
)
0.26
" The dosage of analgesic compound required to control each episode of tension headache was smaller than that of acetaminophen."( Study of a new analgesic compound in the treatment of tension headache.
Borges, J; Zavaleta, C, 1976
)
0.26
" The initial dosage was 24 mg/day for methadone hydrochloride and 800 mg/day for propoxyphene napsylate."( Heroin detoxification. A comparison of propoxyphene and methadone.
Bleich, RN; Casas, SK; Russell, BA; Tennant, FS, 1975
)
0.25
" which is especially dangerous because of repeated dosage by the patient attempting to induce the therapeutic effect more quickly."( Accidental fatal drug poisoning with particular erference to dextropropoxyphene.
Simonsen, J,
)
0.37
" The bioavailability of tablets and a solution of propranolol was compared with a crossover design by obtaining plasma samples at the end of the dosage interval during chronic oral administration of various doses."( Disposition of propoxyphene and propranolol in children.
Atwood, GF; Shand, DG; Wilson, JT, 1976
)
0.26
" Tolerance in terms of withdrawals or side-effect profile did not appear to the dosage of each preparation administered."( The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips.
Costello, F; Eves, MJ; James, IG; Lloyd, RS; Miller, AJ, 1992
)
0.5
" This indicates that although the preparation is hepatotoxic when taken acutely in overdose, in chronic therapeutic dosage it appears to be free from this hazard."( Liver function in patients on long-term paracetamol (co-proxamol) analgesia.
Hutchinson, DR; Parke, DV; Schilds, AF, 1986
)
0.27
"Serious side effects may result from the concurrent administration of the usual dosage of carbamazepine and dextropropoxyphene."( Interaction between carbamazepine and dextropropoxyphene.
Chang, CM; Chin, D; Huang, CY; Woo, E; Yu, YL, 1986
)
0.75
" The mean elimination half-life of dextropropoxyphene after multiple dosing was 35."( Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results.
Crome, P; Flanagan, RJ; Gain, R; Ghurye, R, 1984
)
0.87
"The pre- and postnatal effects of the combined oral administration of propoxyphene (PPX, 100 mg/kg/day) and chlordiazepoxide (CDX, 25, 50 or 100 mg/kg/day) were evaluated in Wistar rats in separate experiments by dosing on days 6 through 21 of pregnancy."( Pre- and postnatal development of rats following concomitant intrauterine exposure to propoxyphene and chlordiazepoxide.
Buttar, HS; Moffatt, JH,
)
0.13
" Although morphine (ID50 = 4 micrograms) was a very potent analgesic when given intracerebroventricularly, very shallow dose-response curves were obtained with the other substances which promoted less than 30% of inhibition at doses up to 250 micrograms."( The peripheral analgesic effect of morphine, codeine, pentazocine and d-propoxyphene.
Ferreira, SH; Lorenzetti, BB; Molina, N; Vettore, O, 1983
)
0.27
" While little information is available concerning P and NP disposition in neonates, dosage estimates based on kinetic and pharmacologic assumptions suggest that the estimated amounts consumed by the neonate after the mother is given the recommended dose of the drug are not likely to result in toxic plasma levels."( Excretion of propoxyphene and norpropoxyphene in breast milk.
Kunka, RL; Ladik, CF; Stern, RM; Venkataramanan, R, 1984
)
0.27
" Both P and NP cumulated during repeated dosing to levels 5 to 7 times those after the first dose."( Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene.
Colburn, WA; Dayton, HE; Inturrisi, CE; O'Brien, CP; Verebey, K; Woody, GE, 1982
)
0.26
"The in vitro release of drugs from controlled-release dosage forms has been studied in terms of a diffusion model."( Mathematical model for in vitro drug release from controlled release dosage forms applied to propoxyphene hydrochloride pellets.
Bechgaard, H; Christensen, FN; Hansen, FY, 1982
)
0.26
" The manufacturer's present recommended dosage may not be sufficient to reverse the effects of large narcotic ingestions."( Naloxone: underdosage after narcotic poisoning.
Conner, CS; Moore, RA; Peterson, RG; Rumack, BH, 1980
)
0.26
" Blood propoxyphene and norpropoxyphene levels were determined repeatedly during the sixth dosing interval (before hemodialysis) and during the seventh dosing interval (during hemodialysis)."( Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients.
Giacomini, KM; Gibson, TP; Levy, G, 1980
)
0.26
" As with other drugs, adequate warnings concerning dosage abuse and the concurrent use of alcohol and other drugs must be stressed."( Deaths related to propoxyphene overdose: a ten-year assessment.
Bednarczyk, LR; Wetli, CV, 1980
)
0.26
" Tramadol showed a dose-response for analgesia in both postsurgical and dental pain patients."( Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics.
McQuay, JH; Moore, AR, 1997
)
0.3
" Sixteen patients were administered dextropropoxyphene (DPP) in a dosage ranging from 120 mg to 240 mg daily (group 1), and 16 patients were administered the lowest doses (20 mg daily) of commercially available controlled-release morphine (group 2)."( Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain.
Agnello, A; Dardanoni, G; Garofalo, S; Mercadante, S; Salvaggio, L, 1998
)
2.02
" Dose-response relationships show that higher doses of ibuprofen may be particularly effective."( Postoperative analgesia and vomiting, with special reference to day-case surgery: a systematic review.
McQuay, HJ; Moore, RA, 1998
)
0.3
" Presentation is similar to narcotic over dosage or poisoning."( Accidental dextropropoxyphene poisoning.
Hegde, SR; Karunakara, BP; Maiya, PP; Pradeep, GC, 2003
)
0.71
" Patient-controlled analgesia was used for the first 3 postoperative days in all patients, and the cumulative dosage used was recorded."( Analgesic effect of electroacupuncture in postthoracotomy pain: a prospective randomized trial.
Chan, SK; Lee, TW; Liang, YM; Ng, CS; Sihoe, AD; Wan, IY; Wong, RH; Wong, WW; Yim, AP, 2006
)
0.33
" Age, duration of use and medical comorbidity were better predictors of seizure than dosage of drug or use of multiple drugs."( Disproportionately high rate of epileptic seizure in patients abusing dextropropoxyphene.
Banerjee, A; Basu, D; Harish, T; Mattoo, SK,
)
0.37
" All dosage forms of the drug have now been withdrawn from the United States market."( Food and Drug Administration recommends against the continued use of propoxyphene.
, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoateA propanoate ester that is propyl propanoate substituted by a benzyl and phenyl group at position 1, a methyl group at position 2 and a dimethylamino group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mas-related G-protein coupled receptor member X2Homo sapiens (human)EC50 (µMol)23.50000.14003.73818.9000AID1802708; AID1802709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
sensory perception of painMas-related G-protein coupled receptor member X2Homo sapiens (human)
sleepMas-related G-protein coupled receptor member X2Homo sapiens (human)
positive regulation of cytokinesisMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell degranulationMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell activationMas-related G-protein coupled receptor member X2Homo sapiens (human)
G protein-coupled receptor signaling pathwayMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
neuropeptide bindingMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell secretagogue receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
plasma membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (130)

Assay IDTitleYearJournalArticle
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1136271Analgesic activity in mouse assessed as withdrawal latency at 12.5 to 75 mg/kg, po by Haffner tail clamp method1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23961logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1136246Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 30 mg/kg, po after 2 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132312Analgesic activity in Swiss CD mouse at 100 mg/kg, ip measured 2 hrs post treatment by hot-plate method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID1136284Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, po1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136270Analgesic activity in naloxone treated mouse assessed as withdrawal latency at 12.5 to 75 mg/kg, po1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1137421Analgesic activity in po dosed CD-1 Charles River mouse assessed as inhibition of phenyl-p-benzoquinine-induced writhing administered 15 to 90 mins prior to phenyl-p-benzoquinine challenge measured after 5 mins1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin-10,4'-piperidine] derivatives.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID23959logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1136249Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 30 mg/kg, po after 5 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1136268Toxicity in Sprague-Dawley rat assessed as sedation at 90 mg/kg, po after 4 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1136224Analgesic activity in Sprague-Dawley rat brewer's yeast treated foot assessed as response threshold at 16 to 32 mg/kg, po1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID116667Analgesic activity was measured by phenylquinone writhing test in male Swiss albino mice at a dose of 0.004 mg/Kg, sc1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis of N-[[(substituted-phenyl)carbonyl]amino]-1,2,3,6-tetrahydropyridines with analgesic and hyperglycemic activity.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID23963logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID113549Inhibition of PQW-writhing in mice on subcutaneous administration at dose 10 mg/kg1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
3-(1-Indolinyl)benzylamines: a new class of analgesic agents.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136439Analgesic activity in Swiss albino mouse assessed as inhibition of phenyl-p-benzoquinone-induced writhing at 56 mg/kg, sc administered 30 mins prior challenge relative to vehicle-treated control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Syntheses of N-substituted 2(3,4)-pyridylcarboxylic acid hydrazides with analgesic and antiinflammatory activity.
AID1136266Toxicity in Sprague-Dawley rat assessed as sedation at 90 mg/kg, po after 2 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1133358Analgesic activity in po dosed CF-1 mouse assessed as reduction in phenylquinone-induced writhing responses administered 15 mins prior to phenylquinone challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Analgesic activity of novel spiro heterocycles. 2-Amino-7-oxa-3-thia-1-azaspiro[5,5]undec-1-enes and related compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1132321Analgesic activity in Swiss CD mouse assessed as elevation of response latency at 100 mg/kg, ip measured 0.5 hr post treatment by tail flick method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID1136260Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 90 mg/kg, po after 1 hr relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136257Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 120 mg/kg, po after 3 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136256Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 120 mg/kg, po after 2 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1134065Neuroleptic activity in ip dosed rat assessed as drug required for blocking discriminated jump-out avoidance behavior in after 1 hr1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID1136264Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 90 mg/kg, po after 5 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1132322Analgesic activity in Swiss CD mouse assessed as elevation of response latency at 100 mg/kg, ip measured 2 hrs post treatment by tail flick method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID1136258Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 120 mg/kg, po after 4 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136245Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 30 mg/kg, po after 1 hr relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1136227Analgesic activity in Sprague-Dawley rat normal foot assessed as response threshold at 32 mg/kg, po1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID23971logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1136254Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 60 mg/kg, po after 5 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1136263Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 90 mg/kg, po after 4 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1136255Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 120 mg/kg, po after 1 hr relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID211157Compound was measured as concentration of compound required for 90% growth inhibition of Trichomonas vaginalis; ND=No data1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Some reactions of 1,4-dihydropyridines with organic azides. Synthesis of 2,7-diazabicyclo[4.1.0]hept-3-enes with analgesic and antiprotozoal activity.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1134558Analgesic activity in sc dosed mouse assessed as inhibition of acetic acid-induced writhing1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis of two metabolites of (+)-propoxyphene.
AID1136250Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 60 mg/kg, po after 1 hr relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1133360Analgesic activity against po dosed yeast-induced inflamed foot Sprague-Dawley rat model assessed as increase in pain threshold in inflamed paw measured after 2 hrs1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Analgesic activity of novel spiro heterocycles. 2-Amino-7-oxa-3-thia-1-azaspiro[5,5]undec-1-enes and related compounds.
AID1134068Analgesic activity in rat assessed as median foot shock required to elicit flinch-jump at 17.8 mg/kg, po after 2 hrs1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136269Toxicity in Sprague-Dawley rat assessed as sedation at 90 mg/kg, po after 5 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1132311Analgesic activity in Swiss CD mouse at 100 mg/kg, ip measured 0.5 hr post treatment by hot-plate method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136259Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 120 mg/kg, po after 5 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1137420Analgesic activity in sc dosed CD-1 Charles River mouse assessed as inhibition of phenyl-p-benzoquinine-induced writhing administered 15 to 90 mins prior to phenyl-p-benzoquinine challenge measured after 5 mins1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin-10,4'-piperidine] derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1136267Toxicity in Sprague-Dawley rat assessed as sedation at 90 mg/kg, po after 3 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136251Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 60 mg/kg, po after 2 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136285Antiarthritic activity in Lewis rat assessed as inhibition of adjuvant-induced paw swelling at 50 mg/kg, po qd for 13 days measured on day 141978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136261Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 90 mg/kg, po after 2 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1136248Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 30 mg/kg, po after 4 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1137425Ratio of ED50 for inhibition of phenyl-p-benzoquinine-induced writhing in po dosed CD-1 Charles River mouse to ED50 for inhibition of phenyl-p-benzoquinine-induced writhing in sc dosed CD-1 Charles River mouse1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin-10,4'-piperidine] derivatives.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID116663Analgesic activity was measured on phenylquinone writhing in mice at 56 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Some reactions of 1,4-dihydropyridines with organic azides. Synthesis of 2,7-diazabicyclo[4.1.0]hept-3-enes with analgesic and antiprotozoal activity.
AID23960logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1136253Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 60 mg/kg, po after 4 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1134073Analgesic activity in mouse at 100 mg/kg, ip after 2 hrs by hot plate assay1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID1136252Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 60 mg/kg, po after 3 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1136262Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 90 mg/kg, po after 3 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID1145236Analgesic activity in ip dosed Charles River rat by tail flick test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Analgesic agents. 3. New bridged aminotetralins.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1134071Analgesic activity in dog assessed as rippling of skin at 5 mg/kg, po after 2 hrs by radiant heat assay1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID1136247Analgesic activity in Sprague-Dawley rat assessed as increase in mean reaction time at 30 mg/kg, po after 3 hrs relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23965logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID116652Analgesic activity in mice using phenylquinone writhing test at 56 mg/kg, sc dose1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Synthesis of N-(carbonylamino)-1,2,3,6-tetrahydropyridines with analgesic, antiinflammatory, and hyperglycemic activity.
AID1136265Toxicity in Sprague-Dawley rat assessed as sedation at 90 mg/kg, po after 1 hr relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1134076Analgesic activity in mouse assessed as tail-flick latency period at 100 mg/kg, ip after 2 hrs by by tail flick test1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1802708Intracellular Calcium Mobilization Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
AID1802709PRESTO-Tango Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,353)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901019 (75.31)18.7374
1990's140 (10.35)18.2507
2000's119 (8.80)29.6817
2010's72 (5.32)24.3611
2020's3 (0.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.55 (24.57)
Research Supply Index7.45 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index85.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials226 (15.17%)5.53%
Reviews72 (4.83%)6.00%
Case Studies188 (12.62%)4.05%
Observational4 (0.27%)0.25%
Other1,000 (67.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of Sequential Ascending Dose Levels to Assess the Safety, Tolerability and Electrocardiographic Effects of Propoxyphene Napsylate Capsules (and Its Metabolite Norpropoxyphene) When Admini [NCT01133873]Phase 448 participants (Anticipated)Interventional2010-06-30Terminated
Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial [NCT00652093]Phase 424 participants (Actual)Interventional2008-03-31Terminated(stopped due to Removal of Darvocet from US market)
An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach [NCT00378937]Phase 430 participants (Anticipated)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00652093 (12) [back to overview]Area Under the Curve
NCT00652093 (12) [back to overview]Final Pain
NCT00652093 (12) [back to overview]Modified Brief Pain Inventory (mBPI)- Interference Score
NCT00652093 (12) [back to overview]Oswestry Disability Index (ODI) Score
NCT00652093 (12) [back to overview]Patient Global Assessment (PGA)
NCT00652093 (12) [back to overview]Recovery Time
NCT00652093 (12) [back to overview]Roland Morris Disability Questionnaire (RMDQ)
NCT00652093 (12) [back to overview]Swiss Spinal Stenosis Score- Physical Function
NCT00652093 (12) [back to overview]Swiss Spinal Stenosis Score- Symptom Severity
NCT00652093 (12) [back to overview]Time to First Symptoms (Tfirst) of Moderate Pain
NCT00652093 (12) [back to overview]Total Distance
NCT00652093 (12) [back to overview]Visual Analog Scale (VAS)

Area Under the Curve

Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals (every 30 seconds) subjects were asked what their pain level was according to the NRS. The area under the curve of present pain intensity is the total area combined for the amount of time the subject walked. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale * minutes (Mean)
Opana Then Darvocet Then Placebo76.0
Opana Then Placebo Then Darvocet95.7
Placebo Then Opana Then Darvocet95.0
Placebo Then Darvocet Then Opana86.4
Darvocet Then Opana Then Placebo123.3
Darvocet Then Placebo Then Opana79.6

[back to top]

Final Pain

Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals subjects were asked what their pain level was according to the NRS. When the subject reached their maximum distance, they were asked their NRS score. This was recorded as final pain intensity. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo4.6
Opana Then Placebo Then Darvocet6.6
Placebo Then Opana Then Darvocet6.2
Placebo Then Darvocet Then Opana6.7
Darvocet Then Opana Then Placebo8.0
Darvocet Then Placebo Then Opana7.1

[back to top]

Modified Brief Pain Inventory (mBPI)- Interference Score

The mBPI is a series of questions that rates the severity and impact of pain on daily function. The questionnaire is made up of 4 pain severity items using the NRS scale, and seven 11-point pain interference scales (0 indicating no interference and 10 indicating complete interference). For the interference score, a total score of 10 indicates pain completely interferes with activities. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo3.7
Opana Then Placebo Then Darvocet4.2
Placebo Then Opana Then Darvocet2.7
Placebo Then Darvocet Then Opana4.3
Darvocet Then Opana Then Placebo6.2
Darvocet Then Placebo Then Opana2.8

[back to top]

Oswestry Disability Index (ODI) Score

The ODI is a set of 10 questions each with five choices (maximum score of 5 points per question) designed to determine how back pain has affected the ability to manage everyday life (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, social life, traveling, and change positions). A score of 0 indicates no disability and total score of 50 would indicate 100% disability. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo37.9
Opana Then Placebo Then Darvocet98.4
Placebo Then Opana Then Darvocet38.0
Placebo Then Darvocet Then Opana44.1
Darvocet Then Opana Then Placebo37.0
Darvocet Then Placebo Then Opana29.7

[back to top]

Patient Global Assessment (PGA)

Subjects were asked to rate their low back pain according to the PGA. PGA is the impact of disease activity. PGA was measured on a 5-point scale, where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo2.8
Opana Then Placebo Then Darvocet2.8
Placebo Then Opana Then Darvocet3.1
Placebo Then Darvocet Then Opana2.6
Darvocet Then Opana Then Placebo3.3
Darvocet Then Placebo Then Opana2.6

[back to top]

Recovery Time

After the subject completed the treadmill test they were asked to immediately return to the seated position. At this point a timer was started. When the subjects pain level returned to baseline (level of pain subject felt in a seated position before walking) the time was stopped. This was recorded as recovery time. Maximum recovery time is 15 minutes. (NCT00652093)
Timeframe: study visit

Interventionminutes (Mean)
Opana Then Darvocet Then Placebo1.10
Opana Then Placebo Then Darvocet1.50
Placebo Then Opana Then Darvocet2.02
Placebo Then Darvocet Then Opana1.58
Darvocet Then Opana Then Placebo2.15
Darvocet Then Placebo Then Opana1.57

[back to top]

Roland Morris Disability Questionnaire (RMDQ)

The RMDQ consists of 24 yes/no statements about activity limitations due to back pain. These questions center on movement, ambulation, and self-care activities. Positive (yes) answers each contribute 1 point to cumulative score with total scores ranging from 0 (no disability) to 24 (severely disabled). (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo12.8
Opana Then Placebo Then Darvocet15.3
Placebo Then Opana Then Darvocet13.2
Placebo Then Darvocet Then Opana15.2
Darvocet Then Opana Then Placebo13.7
Darvocet Then Placebo Then Opana7.4

[back to top]

Swiss Spinal Stenosis Score- Physical Function

The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The physical function section is a series of 5 questions (maximum 4 points per question) and asks to rate function for each question based on comfortably, sometimes with pain, always with pain, no functional ability. The total score (max=20) is divided by five. The maximum score for the physical function section (max=4) indicates no ability to function. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo2.5
Opana Then Placebo Then Darvocet2.5
Placebo Then Opana Then Darvocet2.6
Placebo Then Darvocet Then Opana2.6
Darvocet Then Opana Then Placebo2.6
Darvocet Then Placebo Then Opana2.2

[back to top]

Swiss Spinal Stenosis Score- Symptom Severity

The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The symptom severity section is a set of 7 questions (maximum score is 5 points per question) and asks to rate pain for each question based on no pain, mild, moderate, severe or very severe pain. The total score (maximum=35) is added up and divided by seven. The maximum score for the symptom severity section (score=5) indicates very severe symptom severity. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo2.6
Opana Then Placebo Then Darvocet2.9
Placebo Then Opana Then Darvocet3.2
Placebo Then Darvocet Then Opana3.2
Darvocet Then Opana Then Placebo3.6
Darvocet Then Placebo Then Opana2.9

[back to top]

Time to First Symptoms (Tfirst) of Moderate Pain

Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured. Patients were excluded from the trial if there pain at rest was greater than or equal to 4/10. (NCT00652093)
Timeframe: study visit

Interventionminutes (Mean)
Opana Then Darvocet Then Placebo1.73
Opana Then Placebo Then Darvocet3.02
Placebo Then Opana Then Darvocet3.93
Placebo Then Darvocet Then Opana2.65
Darvocet Then Opana Then Placebo0.83
Darvocet Then Placebo Then Opana5.43

[back to top]

Total Distance

Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. When the subject reached their maximum distance, the treadmill testing was stopped. This was recorded as total distance based on number of minutes and seconds walked. Minutes was converted to meters based on calculation of defined speed of the treadmill. (NCT00652093)
Timeframe: study visit

Interventionmeters (Mean)
Opana Then Darvocet Then Placebo266.6
Opana Then Placebo Then Darvocet249.5
Placebo Then Opana Then Darvocet177.9
Placebo Then Darvocet Then Opana290.1
Darvocet Then Opana Then Placebo160.8
Darvocet Then Placebo Then Opana294.8

[back to top]

Visual Analog Scale (VAS)

The VAS asked subjects to place a mark indicative of their low back pain during the past day on a 100mm line, with 0mm representing no pain and 100mm representing extreme pain. (NCT00652093)
Timeframe: study visit

Interventionunits on a scale (Mean)
Opana Then Darvocet Then Placebo51.3
Opana Then Placebo Then Darvocet57.9
Placebo Then Opana Then Darvocet56.2
Placebo Then Darvocet Then Opana46.7
Darvocet Then Opana Then Placebo63.3
Darvocet Then Placebo Then Opana55.1

[back to top]